Hemoperfusion Can Control Inflammatory Factors in Patients with COVID-19
Abstract
The prevalence of COVID 19 encouraged physicians and researchers to study the pathology of the disease and changes in patients' immunological factors. What has been proven today is the occurrence of an inflammatory outbreak in the body of patients with this infection, which causes severe immunological reactions in them. Hemoperfusion, as an extracorporeal purification method, has the potential to act as an aid in modulating or controlling this inflammatory phase. Therefore, the present study evaluates the role of hemoperfusion in controlling inflammatory conditions in patients with COVID 19.
[1] Abedini A, Mirtajani SB, Karimzadeh M, Jahangirifard A, Kiani A. Can Hesperidin be the Key to the Treatment of Severe Acute Respiratory Syndrome COV-2?. Biomedical and Biotechnology Research Journal (BBRJ). 2020; 4(5):108-9.
[2] Amirsavadkouhi A, Jahangirifard A, Shahrami R, Safari S, Feizabadi F, Langari ZM, et al. The Role of Hemoperfusion in COVID-19 Infection: A Case Series. Arch Anesth & Crit Care. 2021; 7(3):189-194.
[3] Ankawi G, Neri M, Zhang J, Breglia A, Ricci Z, Ronco C. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Critical Care. 2018; 22(1):262.
[4] Goldfarb D, Matalon D. Principles and techniques applied to enhance elimination. Goldfrank’s toxicologic emergencies: McGraw-Hill, New York; 2006. p. 160-72.
[5] Fiore B, Soncini M, Vesentini S, Penati A, Visconti G, Redaelli A. Multi-scale analysis of the toraymyxin adsorption cartridge. Part II: computational fluid-dynamic study. Int J Artif Organs. 2006; 29(2):251-60.
[6] Lau SK, Lau CC, Chan K-H, Li CP, Chen H, Jin D-Y, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol. 2013; 94(12):2679-90.
[7] Ronco C, Piccinni P, Kellum J. Rationale of extracorporeal removal of endotoxin in sepsis: theory, timing and technique. Contrib Nephrol. 2010; 167:25-34.
[8] Navas A, Ferrer R, Martinez ML, Goma G, Gili G, Masip J, et al. Impact of hemoperfusion with polymyxin B added to hemofiltration in patients with endotoxic shock: a case-control study. Ann Intensive Care. 2018; 8(1):121.
[9] Sharifzadeh K, Farzanegan B, Mirtajani SB, Peyravian F, Jahangirifard A. The Potential Role of Bromelain in the Treatment of SARS-COV-2. Cell Mol Anesth. 2020; 5(4):284-5.
[10] Moshari M, Kiaei MM, Hassani M. Review of the Potential of Hemoperfusion for the Treatment of Patients with Respiratory Infectious Diseases with COVID-19 Approach. Arch Anesth & Crit Care. 2021; 7(3):171-5.
[2] Amirsavadkouhi A, Jahangirifard A, Shahrami R, Safari S, Feizabadi F, Langari ZM, et al. The Role of Hemoperfusion in COVID-19 Infection: A Case Series. Arch Anesth & Crit Care. 2021; 7(3):189-194.
[3] Ankawi G, Neri M, Zhang J, Breglia A, Ricci Z, Ronco C. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Critical Care. 2018; 22(1):262.
[4] Goldfarb D, Matalon D. Principles and techniques applied to enhance elimination. Goldfrank’s toxicologic emergencies: McGraw-Hill, New York; 2006. p. 160-72.
[5] Fiore B, Soncini M, Vesentini S, Penati A, Visconti G, Redaelli A. Multi-scale analysis of the toraymyxin adsorption cartridge. Part II: computational fluid-dynamic study. Int J Artif Organs. 2006; 29(2):251-60.
[6] Lau SK, Lau CC, Chan K-H, Li CP, Chen H, Jin D-Y, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol. 2013; 94(12):2679-90.
[7] Ronco C, Piccinni P, Kellum J. Rationale of extracorporeal removal of endotoxin in sepsis: theory, timing and technique. Contrib Nephrol. 2010; 167:25-34.
[8] Navas A, Ferrer R, Martinez ML, Goma G, Gili G, Masip J, et al. Impact of hemoperfusion with polymyxin B added to hemofiltration in patients with endotoxic shock: a case-control study. Ann Intensive Care. 2018; 8(1):121.
[9] Sharifzadeh K, Farzanegan B, Mirtajani SB, Peyravian F, Jahangirifard A. The Potential Role of Bromelain in the Treatment of SARS-COV-2. Cell Mol Anesth. 2020; 5(4):284-5.
[10] Moshari M, Kiaei MM, Hassani M. Review of the Potential of Hemoperfusion for the Treatment of Patients with Respiratory Infectious Diseases with COVID-19 Approach. Arch Anesth & Crit Care. 2021; 7(3):171-5.
| Files | ||
| Issue | Vol 8 No 2 (2022): Spring |
|
| Section | Letter to Editor | |
| DOI | https://doi.org/10.18502/aacc.v8i2.9162 | |
| Keywords | ||
| COVID19 Hemoperfusion Inflammation | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Hassani M, Hassanzad N, Moshari M. Hemoperfusion Can Control Inflammatory Factors in Patients with COVID-19. Arch Anesth & Crit Care. 2022;8(2):172-173.
